Pharma BD Deal Intelligence

AbbVie Inc. / Stemcentrx, Inc.

2016 · Acquisition/Merger · $9.8B · Complete

Announcement Sentiment

Negative

AbbVie acquired South San Francisco-based Stemcentrx for ~$5.8B (approximately $2B cash + $3.8B AbbVie stock) plus up to $4B in success-based milestones (~$9.8B total). Lead asset Rova-T was an anti-DLL3 ADC in registrational trials for SCLC. Acquisition recorded $4B impairment in 2018-2020 after Phase 3 failures; program ultimately terminated.

Did it work? Outcome assessment

Strategic verdict

Failed to Achieve

Financial impact

Impaired/Written Down

Pipeline outcome

Assets Terminated

Assessment window: 5yr post-close.

Key facts

Announced Apr 28, 2016
Closed Jun 09, 2016
Deal value $9.8B
Deal type Acquisition/Merger
Therapeutic area Small cell lung cancer (SCLC)
Indications Small cell lung cancer (SCLC)
Key assets Rovalpituzumab tesirine (Rova-T)
Mechanism Anti-DLL3 antibody-drug conjugate (ADC)

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals